You are currently viewing a new version of our website. To view the old version click .

166 Results Found

  • Article
  • Open Access
23 Citations
8,547 Views
20 Pages

Radiosensitization of Human Leukemic HL-60 Cells by ATR Kinase Inhibitor (VE-821): Phosphoproteomic Analysis

  • Barbora Šalovská,
  • Ivo Fabrik,
  • Kamila Ďurišová,
  • Marek Link,
  • Jiřina Vávrová,
  • Martina Řezáčová and
  • Aleš Tichý

7 July 2014

DNA damaging agents such as ionizing radiation or chemotherapy are frequently used in oncology. DNA damage response (DDR)—triggered by radiation-induced double strand breaks—is orchestrated mainly by three Phosphatidylinositol 3-kinase-related kinase...

  • Communication
  • Open Access
17 Citations
3,487 Views
12 Pages

The MEK1/2 Inhibitor ATR-002 (Zapnometinib) Synergistically Potentiates the Antiviral Effect of Direct-Acting Anti-SARS-CoV-2 Drugs

  • André Schreiber,
  • Benjamin Ambrosy,
  • Oliver Planz,
  • Sebastian Schloer,
  • Ursula Rescher and
  • Stephan Ludwig

The coronavirus disease 2019 (COVID-19) represents a global public health burden. In addition to vaccination, safe and efficient antiviral treatment strategies to restrict the viral spread within the patient are urgently needed. An alternative approa...

  • Article
  • Open Access
42 Citations
7,537 Views
14 Pages

Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells

  • Brian T. Burgess,
  • Abigail M. Anderson,
  • J. Robert McCorkle,
  • Jianrong Wu,
  • Frederick R. Ueland and
  • Jill M. Kolesar

22 February 2020

Objective: Despite the promise of PARP inhibitors (PARPi) for treating BRCA1/2 mutated ovarian cancer (OC), drug resistance invariably develops. We hypothesized rationale drug combinations, targeting key molecules in DNA repair pathways and the cell...

  • Review
  • Open Access
1 Citations
2,801 Views
33 Pages

ATR-CHK1 Axis Inhibitors in Gastric Cancer Treatment

  • Mateusz Kciuk,
  • Renata Gruszka,
  • Marta Aleksandrowicz,
  • Agnieszka Śliwińska and
  • Renata Kontek

Gastric cancer remains a significant global health challenge, with regional and demographic disparities in incidence, mortality, and treatment outcomes. Despite advances in screening and early detection, prognosis remains poor for many patients, part...

  • Article
  • Open Access
6 Citations
3,493 Views
20 Pages

Ataxia telangiectasia mutated and Rad3-related (ATR), a vital member of the phosphatidylinositol 3-kinase-related kinase (PIKK) family, plays a critical role in the DNA damage response (DDR). Tumor cells with a loss of DDR function or defects in the...

  • Article
  • Open Access
9 Citations
3,545 Views
24 Pages

10 June 2022

Olaparib is a poly (ADP-ribose) polymerase inhibitor (PARPi) that inhibits PARP1/2, leading to replication-induced DNA damage that requires homologous recombination repair. Olaparib is often insufficient to treat BRCA-mutated (BRCAMUT) and BRCA wild-...

  • Article
  • Open Access
12 Citations
5,292 Views
17 Pages

Increased Replication Stress Determines ATR Inhibitor Sensitivity in Neuroblastoma Cells

  • David King,
  • Harriet E. D. Southgate,
  • Saskia Roetschke,
  • Polly Gravells,
  • Leona Fields,
  • Jessica B. Watson,
  • Lindi Chen,
  • Devon Chapman,
  • Daniel Harrison and
  • Daniel Yeomanson
  • + 3 authors

10 December 2021

Despite intensive high-dose multimodal therapy, high-risk neuroblastoma (NB) confers a less than 50% survival rate. This study investigates the role of replication stress in sensitivity to inhibition of Ataxia telangiectasia and Rad3-related (ATR) in...

  • Feature Paper
  • Article
  • Open Access
33 Citations
6,316 Views
13 Pages

20 August 2018

Ataxia telangiectasia mutated and Rad3 related kinase (ATR) signals replication stress and DNA damage to S and G2 arrest and promotes DNA repair. Mutations in p53, critical for G1 checkpoint control, are common in cancer and predicted to confer vulne...

  • Article
  • Open Access
12 Citations
4,169 Views
13 Pages

The Role of ATR Inhibitors in Ovarian Cancer: Investigating Predictive Biomarkers of Response

  • Alice Bradbury,
  • Frank T. Zenke,
  • Nicola J. Curtin and
  • Yvette Drew

1 August 2022

Ataxia telangiectasia and Rad-3 related kinase (ATR) signals DNA lesions and replication stress (RS) to the S and G2/M checkpoints and DNA repair pathways making it a promising target to exploit the dysregulated DNA damage response in cancer. ATR inh...

  • Article
  • Open Access
24 Citations
5,368 Views
16 Pages

Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer

  • Jin Hur,
  • Mithun Ghosh,
  • Tae Heon Kim,
  • Nahee Park,
  • Kamal Pandey,
  • Young Bin Cho,
  • Sa Deok Hong,
  • Nar Bahadur Katuwal,
  • Minsil Kang and
  • Hee Jung An
  • + 1 author

27 January 2021

Epithelial ovarian cancer remains the leading cause of mortality among all gynecologic malignancies owing to recurrence and ultimate development of chemotherapy resistance in the majority of patients. In the chemotherapy-resistant ovarian cancer prec...

  • Article
  • Open Access
30 Citations
6,781 Views
17 Pages

28 April 2020

Background: High risk neuroblastoma (HR-NB) is one the most difficult childhood cancers to cure. These tumours frequently present with DNA damage response (DDR) defects including loss or mutation of key DDR genes, oncogene-induced replication stress...

  • Article
  • Open Access
28 Citations
7,956 Views
20 Pages

19 December 2020

Poly (ADP-ribose) polymerase inhibitor (PARPi, olaparib) impairs the repair of DNA single-strand breaks (SSBs), resulting in double-strand breaks (DSBs) that cannot be repaired efficiently in homologous recombination repair (HRR)-deficient cancers su...

  • Review
  • Open Access
12 Citations
8,522 Views
19 Pages

Targeting ATR Pathway in Solid Tumors: Evidence of Improving Therapeutic Outcomes

  • Dimitra Mavroeidi,
  • Anastasia Georganta,
  • Emmanouil Panagiotou,
  • Konstantinos Syrigos and
  • Vassilis L. Souliotis

27 February 2024

The DNA damage response (DDR) system is a complicated network of signaling pathways that detects and repairs DNA damage or induces apoptosis. Critical regulators of the DDR network include the DNA damage kinases ataxia telangiectasia mutated Rad3-rel...

  • Review
  • Open Access
189 Citations
20,870 Views
25 Pages

Targeting the ATR-CHK1 Axis in Cancer Therapy

  • Stuart Rundle,
  • Alice Bradbury,
  • Yvette Drew and
  • Nicola J. Curtin

27 April 2017

Targeting the DNA damage response (DDR) is a new therapeutic approach in cancer that shows great promise for tumour selectivity. Key components of the DDR are the ataxia telangiectasia mutated and Rad3 related (ATR) and checkpoint kinase 1 (CHK1) kin...

  • Review
  • Open Access
54 Citations
18,893 Views
24 Pages

28 April 2010

ATR is an apical kinase in one of the DNA-damage induced checkpoint pathways. Despite the development of inhibitors of kinases structurally related to ATR, as well as inhibitors of the ATR substrate Chk1, no ATR inhibitors have yet been developed. He...

  • Review
  • Open Access
10 Citations
5,410 Views
19 Pages

Unleashing the Power of Synthetic Lethality: Augmenting Treatment Efficacy through Synergistic Integration with Chemotherapy Drugs

  • Yajing Du,
  • Lulu Luo,
  • Xinru Xu,
  • Xinbing Yang,
  • Xueni Yang,
  • Shizheng Xiong,
  • Jiafeng Yu,
  • Tingming Liang and
  • Li Guo

Cancer is the second leading cause of death in the world, and chemotherapy is one of the main methods of cancer treatment. However, the resistance of cancer cells to chemotherapeutic drugs has always been the main reason affecting the therapeutic eff...

  • Feature Paper
  • Review
  • Open Access
66 Citations
11,711 Views
22 Pages

Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in Cancer

  • Lukas Gorecki,
  • Martin Andrs and
  • Jan Korabecny

14 February 2021

Selective killing of cancer cells while sparing healthy ones is the principle of the perfect cancer treatment and the primary aim of many oncologists, molecular biologists, and medicinal chemists. To achieve this goal, it is crucial to understand the...

  • Article
  • Open Access
31 Citations
4,452 Views
18 Pages

1 September 2020

DNA damage response inhibitors (DDRi) may selectively enhance the inactivation of tumor cells in combination with ionizing radiation (IR). The induction of senescence may be the key mechanism of tumor cell inactivation in this combinatorial treatment...

  • Review
  • Open Access
90 Citations
11,081 Views
13 Pages

ATM-Deficient Cancers Provide New Opportunities for Precision Oncology

  • Nicholas R. Jette,
  • Mehul Kumar,
  • Suraj Radhamani,
  • Greydon Arthur,
  • Siddhartha Goutam,
  • Steven Yip,
  • Michael Kolinsky,
  • Gareth J. Williams,
  • Pinaki Bose and
  • Susan P. Lees-Miller

14 March 2020

Poly-ADP ribose polymerase (PARP) inhibitors are currently used in the treatment of several cancers carrying mutations in the breast and ovarian cancer susceptibility genes BRCA1 and BRCA2, with many more potential applications under study and in cli...

  • Review
  • Open Access
35 Citations
7,039 Views
22 Pages

Everything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targeting Agents

  • Federica Martorana,
  • Leandro Apolinario Da Silva,
  • Cristiana Sessa and
  • Ilaria Colombo

14 February 2022

Targeting the inherent vulnerability of cancer cells with an impaired DNA Damage Repair (DDR) machinery, Poly-ADP-Ribose-Polymerase (PARP) inhibitors have yielded significant results in several tumor types, eventually entering clinical practice for t...

  • Article
  • Open Access
1 Citations
1,641 Views
18 Pages

Targeting Ataxia Telangiectasia-Mutated and Rad3-Related for Anaplastic Thyroid Cancer

  • Shu-Fu Lin,
  • Chuen Hsueh,
  • Wei-Yi Chen,
  • Ting-Chao Chou and
  • Richard J. Wong

22 January 2025

Background: Anaplastic thyroid cancer (ATC) is one of the most aggressive human malignancies and has a poor prognosis. Ataxia telangiectasia mutated and Rad3 related (ATR) is a key regulator for the DNA damage response and a potential target to treat...

  • Review
  • Open Access
567 Views
27 Pages

Targeting DNA Damage Response and Immune Crosstalk in Cancer: Mechanistic Insights and Therapeutic Opportunities

  • Lavinia Marcut,
  • Roxana Daniela Brata,
  • Alina Cristina Barb,
  • Alexia Manole,
  • Dan Gabriel Stef,
  • Cristina Stefania Dumitru,
  • Flavia Zara and
  • Raul Patrascu

21 November 2025

Cancer progression and therapeutic resistance are driven by complex molecular interactions between genomic instability and immune modulation. Defects in the DNA damage response (DDR) not only promote tumor heterogeneity but also shape the tumor immun...

  • Review
  • Open Access
8 Citations
4,021 Views
30 Pages

20 April 2023

Endometrial cancer (EC) is increasingly undermining female health worldwide, with poor survival rates for advanced or recurrent/metastatic diseases. The application of immune checkpoint inhibitors (ICIs) has opened a window of opportunity for patient...

  • Review
  • Open Access
13 Citations
5,972 Views
20 Pages

26 April 2022

Targeted therapies against components of the mitogen-activated protein kinase (MAPK) pathway and immunotherapies, which block immune checkpoints, have shown important clinical benefits in melanoma patients. However, most patients develop resistance,...

  • Review
  • Open Access
19 Citations
5,744 Views
22 Pages

Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer?

  • Peter H. Goff,
  • Rashmi Bhakuni,
  • Thomas Pulliam,
  • Jung Hyun Lee,
  • Evan T. Hall and
  • Paul Nghiem

8 July 2021

Metastatic cancers resistant to immunotherapy require novel management strategies. DNA damage response (DDR) proteins, including ATR (ataxia telangiectasia and Rad3-related), ATM (ataxia telangiectasia mutated) and DNA-PK (DNA-dependent protein kinas...

  • Article
  • Open Access
31 Citations
5,079 Views
15 Pages

Kinase Inhibitors of DNA-PK, ATM and ATR in Combination with Ionizing Radiation Can Increase Tumor Cell Death in HNSCC Cells While Sparing Normal Tissue Cells

  • Eva-Maria Faulhaber,
  • Tina Jost,
  • Julia Symank,
  • Julian Scheper,
  • Felix Bürkel,
  • Rainer Fietkau,
  • Markus Hecht and
  • Luitpold V. Distel

17 June 2021

(1) Kinase inhibitors (KI) targeting components of the DNA damage repair pathway are a promising new type of drug. Combining them with ionizing radiation therapy (IR), which is commonly used for treatment of head and neck tumors, could improve tumor...

  • Review
  • Open Access
23 Citations
6,458 Views
13 Pages

DNA-targeted drugs constitute a specialized category of pharmaceuticals developed for cancer treatment, directly influencing various cellular processes involving DNA. These drugs aim to enhance treatment efficacy and minimize side effects by specific...

  • Article
  • Open Access
14 Citations
4,152 Views
22 Pages

Benzothiazole and Chromone Derivatives as Potential ATR Kinase Inhibitors and Anticancer Agents

  • Mykhaylo Frasinyuk,
  • Dimple Chhabria,
  • Victor Kartsev,
  • Haritha Dilip,
  • Samvel N. Sirakanyan,
  • Sivapriya Kirubakaran,
  • Anthi Petrou,
  • Athina Geronikaki and
  • Domenico Spinelli

20 July 2022

Despite extensive studies and the great variety of existing anticancer agents, cancer treatment remains an aggravating and challenging problem. Therefore, the development of novel anticancer drugs with a better therapeutic profile and fewer side effe...

  • Article
  • Open Access
14 Citations
6,980 Views
16 Pages

Targeting DNA damage and response (DDR) pathway has become an attractive approach in cancer therapy. The key mediators involved in this pathway are ataxia telangiectasia-mutated kinase (ATM) and ataxia telangiectasia-mutated, Rad3-related kinase (ATR...

  • Article
  • Open Access
13 Citations
3,453 Views
14 Pages

The ATR Inhibitor VE-821 Enhances the Radiosensitivity and Suppresses DNA Repair Mechanisms of Human Chondrosarcoma Cells

  • Birgit Lohberger,
  • Dietmar Glänzer,
  • Nicole Eck,
  • Katharina Stasny,
  • Anna Falkner,
  • Andreas Leithner and
  • Dietmar Georg

24 January 2023

To overcome the resistance to radiotherapy in chondrosarcomas, the prevention of efficient DNA repair with an additional treatment was explored for particle beams as well as reference X-ray irradiation. The combined treatment with DNA repair inhibito...

  • Article
  • Open Access
4 Citations
3,262 Views
31 Pages

Uncovering miRNA–mRNA Regulatory Networks Related to Olaparib Resistance and Resensitization of BRCA2MUT Ovarian Cancer PEO1-OR Cells with the ATR/CHK1 Pathway Inhibitors

  • Łukasz Biegała,
  • Damian Kołat,
  • Arkadiusz Gajek,
  • Elżbieta Płuciennik,
  • Agnieszka Marczak,
  • Agnieszka Śliwińska,
  • Michał Mikula and
  • Aneta Rogalska

17 May 2024

Resistance to olaparib is the major obstacle in targeted therapy for ovarian cancer (OC) with poly(ADP-ribose) polymerase inhibitors (PARPis), prompting studies on novel combination therapies to enhance olaparib efficacy. Despite identifying various...

  • Proceeding Paper
  • Open Access
1,653 Views
7 Pages

Myeloproliferative neoplasms (MPNs) are a group of haematological malignancies arising from haematopoietic stem cells (HSCs) with acquired driver mutations in JAK2, MPL and CALR. Current therapies are not selective for the mutant HSC population. Incr...

  • Article
  • Open Access
16 Citations
4,910 Views
15 Pages

Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells

  • Michela Chiappa,
  • Federica Guffanti,
  • Martina Anselmi,
  • Monica Lupi,
  • Nicolò Panini,
  • Lisa Wiesmüller and
  • Giovanna Damia

1 April 2022

Background. Poly(ADP-ribose) polymerases inhibitor (PARPi) have shown clinical efficacy in ovarian carcinoma, especially in those harboring defects in homologous recombination (HR) repair, including BRCA1 and BRCA2 mutated tumors. There is increasing...

  • Review
  • Open Access
11 Citations
5,660 Views
18 Pages

Targeting Cell Cycle Checkpoint Kinases to Overcome Intrinsic Radioresistance in Brain Tumor Cells

  • Tijana Vlatkovic,
  • Marlon R. Veldwijk,
  • Frank A. Giordano and
  • Carsten Herskind

29 January 2022

Radiation therapy is an important part of the standard of care treatment of brain tumors. However, the efficacy of radiation therapy is limited by the radioresistance of tumor cells, a phenomenon held responsible for the dismal prognosis of the most...

  • Review
  • Open Access
62 Citations
12,440 Views
28 Pages

1 February 2022

DNA damage response (DDR) is critical to ensure genome stability, and defects in this signaling pathway are highly associated with carcinogenesis and tumor progression. Nevertheless, this also provides therapeutic opportunities, as cells with defecti...

  • Review
  • Open Access
5 Citations
3,601 Views
16 Pages

Genes participating in the cellular response to damaged DNA have an important function to protect genetic information from alterations due to extrinsic and intrinsic cellular insults. In cancer cells, alterations in these genes are a source of geneti...

  • Feature Paper
  • Article
  • Open Access
8 Citations
4,449 Views
14 Pages

The electroanalytical and surface characterization of copper immersed in 3 wt.% NaCl solution containing 1 mM of 2-phenylimidazole (2PhI) is presented. It was proven that 2PhI can be employed as corrosion inhibitor for copper using various electroche...

  • Review
  • Open Access
99 Citations
15,299 Views
26 Pages

18 August 2015

Cancer treatments such as radiotherapy and most of the chemotherapies act by damaging DNA of cancer cells. Upon DNA damage, cells stop proliferation at cell cycle checkpoints, which provides them time for DNA repair. Inhibiting the checkpoint allows...

  • Review
  • Open Access
79 Citations
19,204 Views
56 Pages

DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles’ Heel of Cancer

  • Denis Velic,
  • Anthony M. Couturier,
  • Maria Tedim Ferreira,
  • Amélie Rodrigue,
  • Guy G. Poirier,
  • Fabrice Fleury and
  • Jean-Yves Masson

20 November 2015

For decades, radiotherapy and chemotherapy were the two only approaches exploiting DNA repair processes to fight against cancer. Nowadays, cancer therapeutics can be a major challenge when it comes to seeking personalized targeted medicine that is bo...

  • Article
  • Open Access
689 Views
17 Pages

23 September 2025

The combination of electrochemical, surface, and spectroscopic techniques revealed that Pseudomonas aeruginosa biofilm accelerated corrosion of 304 stainless steel (SS), leading to localized pitting with depths up to 3.75 μm. Such damage did not o...

  • Article
  • Open Access
3 Citations
3,794 Views
15 Pages

RAD50 Loss of Function Variants in the Zinc Hook Domain Associated with Higher Risk of Familial Esophageal Squamous Cell Carcinoma

  • Josephine Mun Yee Ko,
  • Shiu Yeung Lam,
  • Lvwen Ning,
  • Annie Wai Yeeng Chai,
  • Lisa Chan Lei,
  • Sheyne Sta Ana Choi,
  • Carissa Wing Yan Wong and
  • Maria Li Lung

21 September 2021

Unbiased whole-exome sequencing approaches in familial esophageal squamous cell carcinoma (ESCC) initially prioritized RAD50 as a candidate cancer predisposition gene. The combined study with 3289 Henan individuals from Northern China identified two...

  • Article
  • Open Access
2 Citations
3,928 Views
18 Pages

Multiplexed-Based Assessment of DNA Damage Response to Chemotherapies Using Cell Imaging Cytometry

  • Nadia Vezzio-Vié,
  • Marie-Alice Kong-Hap,
  • Eve Combès,
  • Augusto Faria Andrade,
  • Maguy Del Rio,
  • Philippe Pasero,
  • Charles Theillet,
  • Céline Gongora and
  • Philippe Pourquier

The current methods for measuring the DNA damage response (DDR) are relatively labor-intensive and usually based on Western blotting, flow cytometry, and/or confocal immunofluorescence analyses. They require many cells and are often limited to the as...

  • Review
  • Open Access
13 Citations
6,334 Views
15 Pages

Recent Advances in Synergistic Antitumor Effects Exploited from the Inhibition of Ataxia Telangiectasia and RAD3-Related Protein Kinase (ATR)

  • Li-Wei Wang,
  • Songwei Jiang,
  • Ying-Hui Yuan,
  • Jilong Duan,
  • Nian-Dong Mao,
  • Zi Hui,
  • Renren Bai,
  • Tian Xie and
  • Xiang-Yang Ye

12 April 2022

As one of the key phosphatidylinositol 3-kinase-related kinases (PIKKs) family members, ataxia telangiectasia and RAD3-related protein kinase (ATR) is crucial in maintaining mammalian cell genomic integrity in DNA damage response (DDR) and repair pat...

  • Article
  • Open Access
18 Citations
5,174 Views
22 Pages

Differential Effects of Combined ATR/WEE1 Inhibition in Cancer Cells

  • Gro Elise Rødland,
  • Sissel Hauge,
  • Grete Hasvold,
  • Lilli T. E. Bay,
  • Tine T. H. Raabe,
  • Mrinal Joel and
  • Randi G. Syljuåsen

28 July 2021

Inhibitors of WEE1 and ATR kinases are considered promising for cancer treatment, either as monotherapy or in combination with chemo- or radiotherapy. Here, we addressed whether simultaneous inhibition of WEE1 and ATR might be advantageous. Effects o...

  • Review
  • Open Access
15 Citations
9,616 Views
22 Pages

Triple-Negative Breast Cancer and Emerging Therapeutic Strategies: ATR and CHK1/2 as Promising Targets

  • Amalia Sofianidi,
  • Ecaterina E. Dumbrava,
  • Konstantinos N. Syrigos and
  • Azadeh Nasrazadani

13 March 2024

Worldwide, breast cancer is the most frequently diagnosed malignancy in women, with triple-negative breast cancer (TNBC) being the most aggressive molecular subtype. Due to the dearth of effective therapeutic options for TNBC, novel agents targeting...

  • Review
  • Open Access
6 Citations
4,795 Views
20 Pages

The DNA damage response (DDR) is recognized as having an important role in cancer growth and treatment. ATR (ataxia telangiectasia mutated and Rad3-related) kinase, a major regulator of DDR, has shown significant therapeutic potential in cancer treat...

  • Review
  • Open Access
1 Citations
3,181 Views
18 Pages

19 October 2024

Ataxia Telangiectasia and Rad3-related protein (ATR) is an apical kinase of the DNA Damage Response (DDR) pathway responsible for detecting and resolving damaged DNA. Because cancer cells depend heavily on the DNA damage checkpoint for their unchecke...

  • Review
  • Open Access
10 Citations
4,682 Views
20 Pages

ATR Inhibitors in Platinum-Resistant Ovarian Cancer

  • Siyu Li,
  • Tao Wang,
  • Xichang Fei and
  • Mingjun Zhang

29 November 2022

Platinum-resistant ovarian cancer (PROC) is one of the deadliest types of epithelial ovarian cancer, and it is associated with a poor prognosis as the median overall survival (OS) is less than 12 months. Targeted therapy is a popular emerging treatme...

  • Article
  • Open Access
13 Citations
4,104 Views
15 Pages

Therapeutic Vulnerability to ATR Inhibition in Concurrent NF1 and ATRX-Deficient/ALT-Positive High-Grade Solid Tumors

  • Ming Yuan,
  • Charles G. Eberhart,
  • Christine A. Pratilas,
  • Jaishri O. Blakeley,
  • Christine Davis,
  • Marija Stojanova,
  • Karlyne Reilly,
  • Alan K. Meeker,
  • Christopher M. Heaphy and
  • Fausto J. Rodriguez

19 June 2022

Subsets of Neurofibromatosis Type 1 (NF1)-associated solid tumors have been shown to display high frequencies of ATRX mutations and the presence of alternative lengthening of telomeres (ALT). We studied the phenotype of combined NF1 and ATRX deficien...

  • Article
  • Open Access
5 Citations
3,013 Views
15 Pages

25 May 2023

Minute Virus of Mice (MVM) is an autonomous parvovirus of the Parvoviridae family that replicates in mouse cells and transformed human cells. MVM genomes localize to cellular sites of DNA damage with the help of their essential non-structural phospho...

of 4